Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Immune Checkpoint Inhibitor Therapy
100%
Memory CD4+ T Cells
100%
CD45RA
50%
Tumor
33%
Flow Cytometry
33%
Cytotoxic Agents
33%
CD4+ T Cells
33%
Peripheral CD4+ T Cells
33%
Programmed Death-ligand 1 Expression
33%
Expression Level
16%
Programmed Death-ligand 1 (PD-L1)
16%
Clinical Factors
16%
Mutation Status
16%
Immune Checkpoint Inhibitors
16%
Blood Samples
16%
Progression-free Survival
16%
Performance Status
16%
Cox Proportional Hazards Model
16%
Risk Reduction
16%
Gene Therapy
16%
Risk of Progression
16%
Combined Therapy
16%
Treatment Response Prediction
16%
Epidermal Growth Factor Receptor Gene
16%
CCR7
16%
Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Non Small Cell Lung Cancer
100%
Memory T Cell
100%
T-Helper Cell
57%
Neoplasm
28%
Flow Cytometry
28%
Cytotoxic Agent
28%
Programmed Death 1 Ligand 1
28%
Proportional Hazards Model
14%
Treatment Response
14%
Progression Free Survival
14%
Epidermal Growth Factor Receptor
14%
Observational Study
14%
Receptor Gene
14%
Combined Therapy
14%
Biochemistry, Genetics and Molecular Biology
CD4
100%
Immune Checkpoints
100%
Memory T Cell
100%
T Cell
57%
Flow Cytometry
28%
Epidermal Growth Factor Receptor
14%
Receptor Gene
14%
Observational Study
14%
Progression Free Survival
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Non Small Cell Lung Cancer
100%
Neoplasm
28%
Flow Cytometry
28%
Cytotoxic Agent
28%
Programmed Death 1 Ligand 1
28%
Progression Free Survival
14%
Epidermal Growth Factor Receptor
14%
Observational Study
14%